The normal mitral valve permits unrestricted antegrade diastolic flow from the left atrium to the left ventricle (LV) and effectively seals off the atrium from the ventricle during LV systole ...

Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s ...

Tricuspid regurgitation (TR) is common in patients with atrial functional mitral regurgitation (AFMR). However, very few studies have explored its clinical characteristics, determinants, and ...

Cardiac Dimensions announced today that it closed an oversubscribed Series E financing round worth $53 million.

Tricuspid valve regurgitation occurs when blood abnormally flows backwards from the right ventricle into the right atrium through a diseased tricuspid valve. Tricuspid regurgitation can be organic ...

Cardiac Dimensions has about 70 employees globally: 40 in Kirkland, 10 throughout the United States, and 20 in Europe.

KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions ®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an ...

On February 8 cardiac surgery utilizing cardiopulmonary bypass was performed. The mitral valve was found to be stenosed and heavily calcified, and was replaced with a 3M Starr–Edwards prosthesis.

Cardiac Dimensions ®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an oversubscribed $53 million Series E ...